{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T15:20:18Z","timestamp":1783351218534,"version":"3.54.6"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,24]]},"DOI":"10.7759\/cureus.105789","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:20:43Z","timestamp":1774398043000},"source":"Crossref","is-referenced-by-count":1,"title":["Glucagon-Like Peptide-1 Receptor Agonists for Bile Acid Diarrhea: Emerging Evidence and Clinical Implications"],"prefix":"10.7759","author":[{"given":"Eunice K","family":"Omeludike","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cherechi O","family":"Nwabueze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nneoma","family":"Ubah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nzubechukwu","family":"Okeke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunice","family":"Aregbesola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chimezie  R","family":"Onyiaorah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mesoma A","family":"Igbokwe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meher","family":"Gujral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ridwan A","family":"Lawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yetunde F","family":"Akande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2017-315909","article-title":"Guidelines for the investigation of chronic diarrhoea in adults: British Society of Gastroenterology, 3rd edition","volume":"67","author":"Arasaradnam RP","year":"2018","unstructured":"Arasaradnam RP, Brown S, Forbes A, et al.. Guidelines for the investigation of chronic diarrhoea in adults: British Society of Gastroenterology, 3rd edition. Gut. 2018, 67:1380-99. 10.1136\/gutjnl-2017-315909","journal-title":"Gut"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.5009\/gnl14397","article-title":"Bile acid diarrhea: prevalence, pathogenesis, and therapy","volume":"9","author":"Camilleri M","year":"2015","unstructured":"Camilleri M. Bile acid diarrhea: prevalence, pathogenesis, and therapy. Gut Liver. 2015, 9:332-9. 10.5009\/gnl14397","journal-title":"Gut Liver"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1136\/flgastro-2020-101436","article-title":"Bile acid diarrhoea: pathophysiology, diagnosis and management","volume":"12","author":"Farrugia A","year":"2021","unstructured":"Farrugia A, Arasaradnam R. Bile acid diarrhoea: pathophysiology, diagnosis and management. Frontline Gastroenterol. 2021, 12:500-7. 10.1136\/flgastro-2020-101436","journal-title":"Frontline Gastroenterol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13227","article-title":"Systematic review with meta-analysis: the prevalence of bile acid malabsorption in the irritable bowel syndrome with diarrhoea","volume":"42","author":"Slattery SA","year":"2015","unstructured":"Slattery SA, Niaz O, Aziz Q, Ford AC, Farmer AD. Systematic review with meta-analysis: the prevalence of bile acid malabsorption in the irritable bowel syndrome with diarrhoea. Aliment Pharmacol Ther. 2015, 42:3-11. 10.1111\/apt.13227","journal-title":"Aliment Pharmacol Ther"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgast-2016-000116","article-title":"How bad is bile acid diarrhoea: an online survey of patient-reported symptoms and outcomes","volume":"4","author":"Bannaga A","year":"2017","unstructured":"Bannaga A, Kelman L, O'Connor M, Pitchford C, Walters JR, Arasaradnam RP. How bad is bile acid diarrhoea: an online survey of patient-reported symptoms and outcomes. BMJ Open Gastroenterol. 2017, 4:e000116. 10.1136\/bmjgast-2016-000116","journal-title":"BMJ Open Gastroenterol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2019.07.004","article-title":"AGA clinical practice guidelines on the laboratory evaluation of functional diarrhea and diarrhea-predominant irritable bowel syndrome in adults (IBS-D)","volume":"157","author":"Smalley W","year":"2019","unstructured":"Smalley W, Falck-Ytter C, Carrasco-Labra A, Wani S, Lytvyn L, Falck-Ytter Y. AGA clinical practice guidelines on the laboratory evaluation of functional diarrhea and diarrhea-predominant irritable bowel syndrome in adults (IBS-D). Gastroenterology. 2019, 157:851-4. 10.1053\/j.gastro.2019.07.004","journal-title":"Gastroenterology"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2009.04.024","article-title":"A new mechanism for bile acid diarrhea: defective feedback inhibition of bile acid biosynthesis","volume":"7","author":"Walters JR","year":"2009","unstructured":"Walters JR, Tasleem AM, Omer OS, Brydon WG, Dew T, le Roux CW. A new mechanism for bile acid diarrhea: defective feedback inhibition of bile acid biosynthesis. Clin Gastroenterol Hepatol. 2009, 7:1189-94. 10.1016\/j.cgh.2009.04.024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2009.04081.x","article-title":"Systematic review: the prevalence of idiopathic bile acid malabsorption as diagnosed by SeHCAT scanning in patients with diarrhoea-predominant irritable bowel syndrome","volume":"30","author":"Wedlake L","year":"2009","unstructured":"Wedlake L, A'Hern R, Russell D, Thomas K, Walters JR, Andreyev HJ. Systematic review: the prevalence of idiopathic bile acid malabsorption as diagnosed by SeHCAT scanning in patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2009, 30:707-17. 10.1111\/j.1365-2036.2009.04081.x","journal-title":"Aliment Pharmacol Ther"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12466","article-title":"Fibroblast growth factor 19 in patients with bile acid diarrhoea: a prospective comparison of FGF19 serum assay and SeHCAT retention","volume":"38","author":"Pattni SS","year":"2013","unstructured":"Pattni SS, Brydon WG, Dew T, et al.. Fibroblast growth factor 19 in patients with bile acid diarrhoea: a prospective comparison of FGF19 serum assay and SeHCAT retention. Aliment Pharmacol Ther. 2013, 38:967-76. 10.1111\/apt.12466","journal-title":"Aliment Pharmacol Ther"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14214","article-title":"Performance characteristics of serum C4 and FGF19 measurements to exclude the diagnosis of bile acid diarrhoea in IBS-diarrhoea and functional diarrhoea","volume":"46","author":"Vijayvargiya P","year":"2017","unstructured":"Vijayvargiya P, Camilleri M, Carlson P, et al.. Performance characteristics of serum C4 and FGF19 measurements to exclude the diagnosis of bile acid diarrhoea in IBS-diarrhoea and functional diarrhoea. Aliment Pharmacol Ther. 2017, 46:581-8. 10.1111\/apt.14214","journal-title":"Aliment Pharmacol Ther"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000000696","article-title":"The role of bile acids in chronic diarrhea","volume":"115","author":"Camilleri M","year":"2020","unstructured":"Camilleri M, Vijayvargiya P. The role of bile acids in chronic diarrhea. Am J Gastroenterol. 2020, 115:1596-603. 10.14309\/ajg.0000000000000696","journal-title":"Am J Gastroenterol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2014.32","article-title":"Bile acid diarrhoea and FGF19: new views on diagnosis, pathogenesis and therapy","volume":"11","author":"Walters JR","year":"2014","unstructured":"Walters JR. Bile acid diarrhoea and FGF19: new views on diagnosis, pathogenesis and therapy. Nat Rev Gastroenterol Hepatol. 2014, 11:426-34. 10.1038\/nrgastro.2014.32","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1101\/gad.1083503","article-title":"Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis","volume":"17","author":"Holt JA","year":"2003","unstructured":"Holt JA, Luo G, Billin AN, et al.. Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. Genes Dev. 2003, 17:1581-91. 10.1101\/gad.1083503","journal-title":"Genes Dev"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2005.09.001","article-title":"Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis","volume":"2","author":"Inagaki T","year":"2005","unstructured":"Inagaki T, Choi M, Moschetta A, et al.. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab. 2005, 2:217-25. 10.1016\/j.cmet.2005.09.001","journal-title":"Cell Metab"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22627","article-title":"Bile acids activate fibroblast growth factor 19 signaling in human hepatocytes to inhibit cholesterol 7alpha-hydroxylase gene expression","volume":"49","author":"Song KH","year":"2009","unstructured":"Song KH, Li T, Owsley E, Strom S, Chiang JY. Bile acids activate fibroblast growth factor 19 signaling in human hepatocytes to inhibit cholesterol 7alpha-hydroxylase gene expression. Hepatology. 2009, 49:297-305. 10.1002\/hep.22627","journal-title":"Hepatology"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/cphy.c120023","article-title":"Bile acid metabolism and signaling","volume":"3","author":"Chiang JY","year":"2013","unstructured":"Chiang JY. Bile acid metabolism and signaling. Compr Physiol. 2013, 3:1191-212. 10.1002\/cphy.c120023","journal-title":"Compr Physiol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2013-305965","article-title":"Increased colonic bile acid exposure: a relevant factor for symptoms and treatment in IBS","volume":"64","author":"Bajor A","year":"2015","unstructured":"Bajor A, T\u00f6rnblom H, Rudling M, Ung KA, Simr\u00e9n M. Increased colonic bile acid exposure: a relevant factor for symptoms and treatment in IBS. Gut. 2015, 64:84-92. 10.1136\/gutjnl-2013-305965","journal-title":"Gut"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1113\/jphysiol.2014.271155","article-title":"Neuro-humoral signalling by bile acids and the TGR5 receptor in the gastrointestinal tract","volume":"592","author":"Bunnett NW","year":"2014","unstructured":"Bunnett NW. Neuro-humoral signalling by bile acids and the TGR5 receptor in the gastrointestinal tract. J Physiol. 2014, 592:2943-50. 10.1113\/jphysiol.2014.271155","journal-title":"J Physiol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/2097359","article-title":"Pros and cons of the SeHCAT test in bile acid diarrhea: a more appropriate use of an old nuclear medicine technique","volume":"2018","author":"Fani B","year":"2018","unstructured":"Fani B, Bertani L, Paglianiti I, et al.. Pros and cons of the SeHCAT test in bile acid diarrhea: a more appropriate use of an old nuclear medicine technique. Gastroenterol Res Pract. 2018, 2018:2097359. 10.1155\/2018\/2097359","journal-title":"Gastroenterol Res Pract"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000000772","article-title":"Biochemical diagnosis of bile acid diarrhea: prospective comparison with the 75seleno-taurohomocholic acid test","volume":"115","author":"Borup C","year":"2020","unstructured":"Borup C, Wildt S, Rumessen J, et al.. Biochemical diagnosis of bile acid diarrhea: prospective comparison with the 75seleno-taurohomocholic acid test. Am J Gastroenterol. 2020, 115:2086-94. 10.14309\/ajg.0000000000000772","journal-title":"Am J Gastroenterol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/485631","article-title":"Bile acid malabsorption in chronic diarrhea: pathophysiology and treatment","volume":"27","author":"Barkun AN","year":"2013","unstructured":"Barkun AN, Love J, Gould M, Pluta H, Steinhart H. Bile acid malabsorption in chronic diarrhea: pathophysiology and treatment. Can J Gastroenterol. 2013, 27:653-9. 10.1155\/2013\/485631","journal-title":"Can J Gastroenterol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2024.07.008","article-title":"Advances in the pathophysiology, diagnosis and management of chronic diarrhoea from bile acid malabsorption: a systematic review","volume":"128","author":"Di Ciaula A","year":"2024","unstructured":"Di Ciaula A, Khalil M, Baffy G, Portincasa P. Advances in the pathophysiology, diagnosis and management of chronic diarrhoea from bile acid malabsorption: a systematic review. Eur J Intern Med. 2024, 128:10-9. 10.1016\/j.ejim.2024.07.008","journal-title":"Eur J Intern Med"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1111\/apt.17740","article-title":"Editorial: Bile acid diarrhoea - simplified clinico-biochemical diagnosis","volume":"59","author":"Camilleri M","year":"2024","unstructured":"Camilleri M. Editorial: Bile acid diarrhoea - simplified clinico-biochemical diagnosis. Aliment Pharmacol Ther. 2024, 59:126-7. 10.1111\/apt.17740","journal-title":"Aliment Pharmacol Ther"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2019.08.062","article-title":"Canadian Association of Gastroenterology clinical practice guideline on the management of bile acid diarrhea","volume":"18","author":"Sadowski DC","year":"2020","unstructured":"Sadowski DC, Camilleri M, Chey WD, et al.. Canadian Association of Gastroenterology clinical practice guideline on the management of bile acid diarrhea. Clin Gastroenterol Hepatol. 2020, 18:24-41.e1. 10.1016\/j.cgh.2019.08.062","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.6154","article-title":"Efficacy of bile acid sequestrants in the treatment of bile acid diarrhea: a meta-analysis of randomized controlled trials","volume":"65","author":"Soares GA","year":"2025","unstructured":"Soares GA, Godoi A, Marcolin P, Piredda G, Laia E, Rodrigues AZ. Efficacy of bile acid sequestrants in the treatment of bile acid diarrhea: a meta-analysis of randomized controlled trials. J Clin Pharmacol. 2025, 65:478-85. 10.1002\/jcph.6154","journal-title":"J Clin Pharmacol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2009.10.020","article-title":"Effects of chenodeoxycholate and a bile acid sequestrant, colesevelam, on intestinal transit and bowel function","volume":"8","author":"Odunsi-Shiyanbade ST","year":"2010","unstructured":"Odunsi-Shiyanbade ST, Camilleri M, McKinzie S, et al.. Effects of chenodeoxycholate and a bile acid sequestrant, colesevelam, on intestinal transit and bowel function. Clin Gastroenterol Hepatol. 2010, 8:159-65. 10.1016\/j.cgh.2009.10.020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2014.05.009","article-title":"Colesevelam for the treatment of bile acid malabsorption-associated diarrhea in patients with Crohn's disease: a randomized, double-blind, placebo-controlled study","volume":"8","author":"Beigel F","year":"2014","unstructured":"Beigel F, Teich N, Howaldt S, et al.. Colesevelam for the treatment of bile acid malabsorption-associated diarrhea in patients with Crohn's disease: a randomized, double-blind, placebo-controlled study. J Crohns Colitis. 2014, 8:1471-9. 10.1016\/j.crohns.2014.05.009","journal-title":"J Crohns Colitis"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(22)00401-0","article-title":"Efficacy and safety of colesevelam for the treatment of bile acid diarrhoea: a double-blind, randomised, placebo-controlled, phase 4 clinical trial","volume":"8","author":"Borup C","year":"2023","unstructured":"Borup C, Vinter-Jensen L, J\u00f8rgensen SP, et al.. Efficacy and safety of colesevelam for the treatment of bile acid diarrhoea: a double-blind, randomised, placebo-controlled, phase 4 clinical trial. Lancet Gastroenterol Hepatol. 2023, 8:321-31. 10.1016\/S2468-1253(22)00401-0","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1177\/1756283X10377126","article-title":"Managing bile acid diarrhoea","volume":"3","author":"Walters JR","year":"2010","unstructured":"Walters JR, Pattni SS. Managing bile acid diarrhoea. Therap Adv Gastroenterol. 2010, 3:349-57. 10.1177\/1756283X10377126","journal-title":"Therap Adv Gastroenterol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1080\/17474124.2024.2402353","article-title":"Managing bile acid diarrhea: aspects of contention","volume":"18","author":"Walters JR","year":"2024","unstructured":"Walters JR, Sikafi R. Managing bile acid diarrhea: aspects of contention. Expert Rev Gastroenterol Hepatol. 2024, 18:521-8. 10.1080\/17474124.2024.2402353","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00034.2006","article-title":"The physiology of glucagon-like peptide 1","volume":"87","author":"Holst JJ","year":"2007","unstructured":"Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007, 87:1409-39. 10.1152\/physrev.00034.2006","journal-title":"Physiol Rev"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1","volume":"27","author":"Drucker DJ","year":"2018","unstructured":"Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018, 27:740-56. 10.1016\/j.cmet.2018.03.001","journal-title":"Cell Metab"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2982.2007.01079.x","article-title":"GLP-1 suppresses gastrointestinal motility and inhibits the migrating motor complex in healthy subjects and patients with irritable bowel syndrome","volume":"20","author":"Hellstr\u00f6m PM","year":"2008","unstructured":"Hellstr\u00f6m PM, N\u00e4slund E, Edholm T, et al.. GLP-1 suppresses gastrointestinal motility and inhibits the migrating motor complex in healthy subjects and patients with irritable bowel syndrome. Neurogastroenterol Motil. 2008, 20:649-59. 10.1111\/j.1365-2982.2007.01079.x","journal-title":"Neurogastroenterol Motil"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1111\/bph.15611","article-title":"Actions of glucagon-like peptide-1 receptor ligands in the gut","volume":"179","author":"Holst JJ","year":"2022","unstructured":"Holst JJ, Andersen DB, Grunddal KV. Actions of glucagon-like peptide-1 receptor ligands in the gut. Br J Pharmacol. 2022, 179:727-42. 10.1111\/bph.15611","journal-title":"Br J Pharmacol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12593","article-title":"Gastrointestinal actions of glucagon-like peptide-1-based therapies: glycaemic control beyond the pancreas","volume":"18","author":"Smits MM","year":"2016","unstructured":"Smits MM, Tonneijck L, Muskiet MH, Kramer MH, Cahen DL, van Raalte DH. Gastrointestinal actions of glucagon-like peptide-1-based therapies: glycaemic control beyond the pancreas. Diabetes Obes Metab. 2016, 18:224-35. 10.1111\/dom.12593","journal-title":"Diabetes Obes Metab"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1113\/jphysiol.2014.270892","article-title":"Physiological underpinnings of irritable bowel syndrome: neurohormonal mechanisms","volume":"592","author":"Camilleri M","year":"2014","unstructured":"Camilleri M. Physiological underpinnings of irritable bowel syndrome: neurohormonal mechanisms. J Physiol. 2014, 592:2967-80. 10.1113\/jphysiol.2014.270892","journal-title":"J Physiol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(22)00198-4","article-title":"Safety and efficacy of liraglutide versus colesevelam for the treatment of bile acid diarrhoea: a randomised, double-blind, active-comparator, non-inferiority clinical trial","volume":"7","author":"K\u00e5rhus ML","year":"2022","unstructured":"K\u00e5rhus ML, Br\u00f8nden A, Forman JL, et al.. Safety and efficacy of liraglutide versus colesevelam for the treatment of bile acid diarrhoea: a randomised, double-blind, active-comparator, non-inferiority clinical trial. Lancet Gastroenterol Hepatol. 2022, 7:922-31. 10.1016\/S2468-1253(22)00198-4","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(22)00213-8","article-title":"Treating bile acid diarrhoea with liraglutide","volume":"7","author":"Walters JR","year":"2022","unstructured":"Walters JR. Treating bile acid diarrhoea with liraglutide. Lancet Gastroenterol Hepatol. 2022, 7:897-9. 10.1016\/S2468-1253(22)00213-8","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.14309\/ctg.0000000000000772","article-title":"Liraglutide and colesevelam change serum and fecal bile acid levels in a randomized trial with patients with bile acid diarrhea","volume":"15","author":"Ellegaard AM","year":"2024","unstructured":"Ellegaard AM, K\u00e5rhus ML, Krych L, et al.. Liraglutide and colesevelam change serum and fecal bile acid levels in a randomized trial with patients with bile acid diarrhea. Clin Transl Gastroenterol. 2024, 15:e00772. 10.14309\/ctg.0000000000000772","journal-title":"Clin Transl Gastroenterol"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-044711","article-title":"Protocol for a randomised, double-blinded, placebo-controlled, double-dummy 6-week clinical trial comparing the treatment effects of the glucagon-like peptide 1 receptor agonist liraglutide versus the bile acid sequestrant colesevelam on bile acid malabsorption","volume":"11","author":"K\u00e5rhus ML","year":"2021","unstructured":"K\u00e5rhus ML, Br\u00f8nden A, Lyng Forman J, Haaber A, Vilsb\u00f8ll T, Sonne DP, Knop FK. Protocol for a randomised, double-blinded, placebo-controlled, double-dummy 6-week clinical trial comparing the treatment effects of the glucagon-like peptide 1 receptor agonist liraglutide versus the bile acid sequestrant colesevelam on bile acid malabsorption. BMJ Open. 2021, 11:e044711. 10.1136\/bmjopen-2020-044711","journal-title":"BMJ Open"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1080\/17474124.2023.2293814","article-title":"Recent developments in diagnosing bile acid diarrhea","volume":"17","author":"Lupianez-Merly C","year":"2023","unstructured":"Lupianez-Merly C, Dilmaghani S, Camilleri M. Recent developments in diagnosing bile acid diarrhea. Expert Rev Gastroenterol Hepatol. 2023, 17:1185-95. 10.1080\/17474124.2023.2293814","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2982.2011.01723.x","article-title":"Efficacy of the glucagon-like peptide-1 agonist exenatide in the treatment of short bowel syndrome","volume":"23","author":"Kunkel D","year":"2011","unstructured":"Kunkel D, Basseri B, Low K, et al.. Efficacy of the glucagon-like peptide-1 agonist exenatide in the treatment of short bowel syndrome. Neurogastroenterol Motil. 2011, 23:739-e328. 10.1111\/j.1365-2982.2011.01723.x","journal-title":"Neurogastroenterol Motil"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1136\/flgastro-2023-102402","article-title":"Emerging uses of glucagon-like peptide 1 (GLP-1) receptor agonists following ileal resection: literature review and case examples","volume":"14","author":"Conley TE","year":"2023","unstructured":"Conley TE, White KL, Bond A, Harrison S, McLaughlin J, Lal S. Emerging uses of glucagon-like peptide 1 (GLP-1) receptor agonists following ileal resection: literature review and case examples. Frontline Gastroenterol. 2023, 14:521-6. 10.1136\/flgastro-2023-102402","journal-title":"Frontline Gastroenterol"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1002\/jpen.2224","article-title":"Bile acid-farnesoid X receptor-fibroblast growth factor 19 axis in patients with short bowel syndrome: the randomized, glepaglutide phase 2 trial","volume":"46","author":"Hvistendahl MK","year":"2022","unstructured":"Hvistendahl MK, Naimi RM, Hansen SH, et al.. Bile acid-farnesoid X receptor-fibroblast growth factor 19 axis in patients with short bowel syndrome: the randomized, glepaglutide phase 2 trial. JPEN J Parenter Enteral Nutr. 2022, 46:923-35. 10.1002\/jpen.2224","journal-title":"JPEN J Parenter Enteral Nutr"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(19)30078-0","article-title":"Disease modifying therapy in short bowel syndrome: finally coming of age?","volume":"4","author":"Vanuytsel T","year":"2019","unstructured":"Vanuytsel T. Disease modifying therapy in short bowel syndrome: finally coming of age?. Lancet Gastroenterol Hepatol. 2019, 4:328-9. 10.1016\/S2468-1253(19)30078-0","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2022.0338","article-title":"Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: a systematic review and meta-analysis of randomized clinical trials","volume":"182","author":"He L","year":"2022","unstructured":"He L, Wang J, Ping F, et al.. Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: a systematic review and meta-analysis of randomized clinical trials. JAMA Intern Med. 2022, 182:513-9. 10.1001\/jamainternmed.2022.0338","journal-title":"JAMA Intern Med"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2024.101242","article-title":"Incretin-based drugs and the risk of gallbladder or biliary tract diseases among patients with type 2 diabetes across categories of body mass index: a nationwide cohort study","volume":"56","author":"Ko HY","year":"2025","unstructured":"Ko HY, Bea S, Yoon D, Hong B, Bae JH, Cho YM, Shin JY. Incretin-based drugs and the risk of gallbladder or biliary tract diseases among patients with type 2 diabetes across categories of body mass index: a nationwide cohort study. Lancet Reg Health West Pac. 2025, 56:101242. 10.1016\/j.lanwpc.2024.101242","journal-title":"Lancet Reg Health West Pac"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1177\/20420188251406456","article-title":"GLP-1 receptor agonists and gallbladder disease risk: insights into molecular mechanisms and clinical implications","volume":"16","author":"Ram\u00edrez-Mej\u00eda MM","year":"2025","unstructured":"Ram\u00edrez-Mej\u00eda MM, Ponciano-Rodriguez G, Eslam M, M\u00e9ndez-S\u00e1nchez N. GLP-1 receptor agonists and gallbladder disease risk: insights into molecular mechanisms and clinical implications. Ther Adv Endocrinol Metab. 2025, 16:20420188251406456. 10.1177\/20420188251406456","journal-title":"Ther Adv Endocrinol Metab"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25031544","article-title":"Bile acid diarrhea: from molecular mechanisms to clinical diagnosis and treatment in the era of precision medicine","volume":"25","author":"Yang D","year":"2024","unstructured":"Yang D, Lyu C, He K, Pang K, Guo Z, Wu D. Bile acid diarrhea: from molecular mechanisms to clinical diagnosis and treatment in the era of precision medicine. Int J Mol Sci. 2024, 25:1544. 10.3390\/ijms25031544","journal-title":"Int J Mol Sci"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2024.12.019","article-title":"Bile acid diarrhea in patients with chronic diarrhea. Current appraisal and recommendations for clinical practice","volume":"57","author":"Barbara G","year":"2025","unstructured":"Barbara G, Bellini M, Portincasa P, et al.. Bile acid diarrhea in patients with chronic diarrhea. Current appraisal and recommendations for clinical practice. Dig Liver Dis. 2025, 57:680-7. 10.1016\/j.dld.2024.12.019","journal-title":"Dig Liver Dis"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/466816-glucagon-like-peptide-1-receptor-agonists-for-bile-acid-diarrhea-emerging-evidence-and-clinical-implications","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:20:44Z","timestamp":1774398044000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/466816-glucagon-like-peptide-1-receptor-agonists-for-bile-acid-diarrhea-emerging-evidence-and-clinical-implications"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,24]]},"references-count":50,"URL":"https:\/\/doi.org\/10.7759\/cureus.105789","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,24]]}}}